Patents by Inventor Yasuhiro Takeshima

Yasuhiro Takeshima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
    Patent number: 9657049
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 23, 2017
    Assignees: Orphan Disease Treatment Institute Co., Ltd., Daiichi Sankyo Company, Limited
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
    Patent number: 9657050
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 23, 2017
    Assignees: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
    Patent number: 9243026
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: January 26, 2016
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS
    Publication number: 20160002636
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Applicants: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi MATSUO, Yasuhiro Takeshima, Makoto Koizumi
  • ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS
    Publication number: 20140316123
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 23, 2014
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA nucleic acid drugs modifying splicing in mRNA precursor
    Patent number: 8624019
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: January 7, 2014
    Assignees: Daiichi Sankyo Company, Limited, Orphan Disease Treatment Institute Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS
    Publication number: 20130090465
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: November 9, 2012
    Publication date: April 11, 2013
    Inventors: Masafumi MATSUO, Yasuhiro Takeshima, Makoto Koizumi
  • ENA nucleic acid drugs modifying splicing in mRNA precursor
    Patent number: 7902160
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: March 8, 2011
    Assignees: Nonprofit Organization Translational Research Organization of Duchenne Muscular Dystrophy, KNC Laboratories Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR
    Publication number: 20110046360
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 24, 2011
    Applicants: Nonpro. Org. Trans. Res. Org. of Duch. Musc. Dys., KNC Laboratories Co., Ltd.
    Inventors: Masafumi MATSUO, Yasuhiro TAKESHIMA, Makoto KOIZUMI
  • Ena nucleic acid drugs modifying splicing in mrna precursor
    Publication number: 20070082861
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: November 21, 2003
    Publication date: April 12, 2007
    Applicants: Masafumi Matsuo, Yasuhiro Takeshima, Nonpro. Org. Trans. Res. Org. of Duch. Musc. Dys.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Medicament for treatment of Duchenne muscular dystrophy
    Patent number: 6653467
    Abstract: Antisense oligonucleotides comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO:1 or NO:2 are disclosed. The antisense oligonucleotides are used for treatment of specific types of Duchenne muscular dystrophy which is attributed to a change in number of the nucleotides composing one or more exons adjacent to exon 43 or 53, respectively, in human dystrophin mRNA, wherein the change is due to deletion of one or more nucleotides from the normal nucleotide sequence for the exons, wherein the net of the change in number of the nucleotides is expressed as a reduction of (3×N+1) nucleotides, wherein N is zero or a natural number.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: November 25, 2003
    Assignees: JCR Pharmaceutical Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima